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higher mortality from bleeding than pulmonary embolism (PE) in
the first 3 months. Although point estimates are low, their obser-
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Sanchez Munoz-Torrero and the RIETE investigators report
that older patients with acute deep vein thrombosis (DVT) have a, Mich
ations may be surprising to most readers. Their findings reaffirm
rior observations that major bleeding events from anticoagula-
ion, particularly vitamin K antagonists (VKAs), occur early in the
ourse of therapy.
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Volume 54, Number 19S Comerota 33SThis robust database has provided enormous insight into the
outcome of patients with DVT and PE. Most recurrences follow
the initial event, that is, patients presenting with PE will have PE as
a recurrent event, and those presenting with DVT recur with DVT.
That was also the case in these patients.
The authors also showed that the diagnosis of DVT carries an
early mortality ranging from 6% to 11% in patients 60 years of
age. The majority of the fatalities that were observed occurred
beyond the first week of therapy; therefore, one would assume that
the majority of the patients were being treated with a VKA. Two
factors on multivariate analysis were found to correlate with fatal
PE: chronic lung disease and malignancy. However, eight factors
were associated with fatal bleeding: age (upper decades), low body
weight, recent major bleeding, renal dysfunction, bilateral DVT,
cancer, immobility 4 days, and prior venous thromboembolism.
Aside from renal dysfunction, low body weight, and recent major
bleeding, it is difficult to integrate the bleeding risk factors to
modify clinical care. The authors tabulated outcome events by
decade of life in Table II. The most impressive discrepancy in
mortality occurred in the patients80 years of age, where major/
fatal bleeding occurred in 3.6% vs thrombotic events in 1.7%.
Eleven percent of this age group died within this 3-month window.It is reasonable to assume that all major bleeding will be
clinically apparent and therefore accurately recognized. However,hat is not the case with fatal PE. To fulfill the definition of fatal PE,
he patients must have experienced an objectively confirmed PE
ollowed by death within 10 days. Therefore, sudden unexplained
eaths, which more commonly would occur out of the hospital,
ould not be recorded as a fatal PE by the authors’ definition. As
hey recognized, the rate of fatal PE may be underestimated. This
s not to detract from the value of this report nor the importance of
he RIETE registry.
The authors observe that in older patients, the risk of fatal
leeding exceeds the risk of fatal PE in patients presenting with
cute DVT. Clinicians might assume that less aggressive anticoag-
lation therapy with VKAs might be indicated. Unfortunately, that
annot be substantiated by observations from a prior randomized
rial.1 It will be interesting to observe how guideline writing
ommittees respond to the important observations reported by the
IETE investigators.
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